XTalks

FEBRUARY 10, 2023

According to a recent review published in Nature , as of April 2022 almost 1,800 active cell therapy clinical trials were listed in ClinicalTrials.gov, a 33 percent increase from 2021. In a recent webinar, Dr. Vassallo discussed the operational considerations for complex cell therapy clinical trials.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Gene Therapy 52

Pharmaceutical Technology

MARCH 1, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

XTalks

AUGUST 29, 2022

Now a common gene editing tool, the popularity of the CRISPR-Cas9 system has increased over the past decade. CRISPR is notable for engineering living cells, allowing scientists to edit, turn off, delete, or replace genes in a cell’s genome.

Gene Editing 98

Gene Editing DNA Gene Genome 98

Drug Discovery World

DECEMBER 20, 2022

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. There will be greater emphasis on diversity in clinical trials. In summary, 2023 could be a very exciting year for life sciences.

Drugs 52

Drugs Gene Editing Clinical Trials Clinical Trials 52

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

Drug Discovery World

MAY 29, 2024

The project will combine Oxford’s academic research capabilities with SpyBiotech’s proprietary SPYVLP platform technology to advance three vaccine candidates targeting EBV and test these in a Phase I clinical trial. Sartorius has been working with NVIDIA since 2020. “Biological interactions are exceptionally complex.

Drugs 52

Drugs Gene Editing Life Science Genome 52

XTalks

MARCH 28, 2024

Building Cancer Awareness and Empowering Métis Youth: Featuring Jordyn Playne, President, Métis Nation of Ontario Youth Council – Xtalks Life Science Podcast Ep. Early clinical trials have shown promising results and this therapy could become a valuable addition towards CRC treatment in the future.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

pharmaphorum

OCTOBER 7, 2020

Drs Emmanuelle Charpentier and Jennifer Doudna have won this year’s Nobel Prize for chemistry in recognition of their work on the gene-editing technology CRISPR/Cas9. In 2011, Emmanuelle Charpentier and Jennifer Doudna had no idea that their first meeting, in a café in Puerto Rico, would be life-changing.

Gene Editing 90

Gene Editing Bacteria DNA Gene 90

XTalks

JANUARY 26, 2024

Innovations in Cancer Therapy CRISPR/Cas9, a groundbreaking gene-editing technology, has demonstrated significant potential in oncology, offering new avenues for cancer treatment. Clinical trials have demonstrated the potential of CRISPR/Cas9 in this field.

Research 118

Research Gene Editing Gene Genetics 118

Drug Discovery World

JANUARY 26, 2023

The modernisation of R&D models could be key to reducing spend on new drugs, a point that Deloitte makes about the need to transform the clinical trials process. At the height of the pandemic, DCTs were seen as a viable alternative to keeping the engines running on clinical trials when non-critical in-person care was paused.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

pharmaphorum

NOVEMBER 23, 2021

It is also close to Cambridge University, seen as one of the world’s leading life sciences research centres, as well as the city’s Addenbrookes Hospital, an important centre for clinical trials in the National Health Service.

Gene Editing 104

Gene Editing Life Science Pharma Companies Clinical Trials 104

Drug Discovery World

SEPTEMBER 6, 2022

As we look to the future, many advanced therapy players are sticking to traditional cell and gene technologies like autologous cell therapies and gene therapy using adeno-associated viral vectors, but some are branching out to other models like allogeneic cell therapies, non-viral delivery methods and gene-editing technologies.

Gene Therapy 52

Gene Therapy Gene Gene Editing Manufacturing 52

XTalks

FEBRUARY 27, 2024

There have been significant advancements in new rare disease drugs, particularly for genetic disorders that can be treated by correcting, replacing or silencing defective genes. The US Food and Drug Administration (FDA) has approved a number of new rare disease drugs in recent years, including gene therapies.

Research 59

Research Drugs Gene Therapy Clinical Trials 59

XTalks

NOVEMBER 3, 2023

CRISPR works as genetic scissors to edit parts of the genome. The CRISPR-Cas9 gene editing system was first discovered to be endogenous in bacteria. Given the system’s powerful ability to make cuts in genes in a precise manner, the system is being leveraged in gene therapies.

Gene Therapy 59

Gene Therapy Gene Gene Editing In-Vivo 59

Drug Discovery World

FEBRUARY 28, 2024

Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. A Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether a type of antibody called IgE could be used to treat cancer.

Development 64

Development Research Drugs Antibody 64

XTalks

NOVEMBER 30, 2023

The safety and efficacy of Cabenuva were established through two randomized, open-label, controlled clinical trials involving 1,182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) before initiating Cabenuva treatment. Additionally, Gag-specific CD8+ T cells demonstrated an increase of 1.7

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Drug Discovery World

SEPTEMBER 6, 2022

The cell and gene therapy industry has experienced exponential growth in the last three years and as funding for the field continues to break records there are no signs of a slowdown. With 2,261 ongoing clinical trials in regenerative medicine, the FDA expects to approve 1 between 10 and 20 new cell and gene therapies a year by 2025.

Gene Therapy 52

Gene Therapy Gene Manufacturing Clinical Trials 52

Drug Discovery World

MAY 23, 2023

We’re seeing a drive towards the allogeneic market with more progressing into clinical trials. Now, we are seeing through trials that a large proportion, if not more than half, are induced pluripotent stem cells (IPSC) derived, which is a huge leap towards off-the-shelf products.

Gene Therapy 52

Gene Therapy Gene Gene Editing Production 52

Drug Discovery World

JULY 18, 2023

These methods offer safer CAR T-based therapies, laying the foundation for clinical trials and the rapid development of a new generation of CAR T cells for both autologous and allogeneic use. This approach achieves knock-in efficiencies at multiple loci (singly or in combination) comparable to AAV-based methods.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

NOVEMBER 24, 2023

It provides inspiration for how fast biopharma organisations can work together with universities and academia globally to meet tight deadlines and move ground-breaking research from concepts to clinical trials. This includes areas such as stem cell therapy, tissue engineering, and gene editing.

Research 59

Research Life Science Gene Editing Vaccination 59

pharmaphorum

JULY 1, 2021

Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, says Debiopharm’s Tanja Dowe. The next decade is where it really starts to get interesting, as we see more and more ‘synbio’-enabled drugs enter clinical trials.

Gene Editing 75

Gene Editing Engineer Development Gene 75

XTalks

DECEMBER 13, 2023

Casgevy’s approval by the FDA is momentous: it is the first CRISPR-based gene-editing therapy to be approved in the US. In the Casgevy trial, 29 of 31 patients who received the treatment experienced freedom from severe VOC episodes for at least 12 consecutive months during the 24-month follow-up period.

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

XTalks

AUGUST 2, 2023

With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. billion ($3.65 billion ($2.85

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MARCH 11, 2021

Speaking at the virtual Capital Markets Day on Wednesday, CEO Werner Baumann emphasized Bayer’s long-term growth perspectives: “Bayer is a leading life science company, uniquely positioned at the intersection of health and nutrition – with attractive prospects for growth, earnings and cash flow.”

Sales 52

Sales Gene Therapy Marketing Gene 52

Drug Discovery World

NOVEMBER 16, 2022

In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process. . The benefits to drug development are obvious then.

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Drug Discovery World

OCTOBER 7, 2022

It is about going faster in progressing our innovation to market, taking things further along the value chain as we de-risk the early science. It’s about working together with our partners in the life science sector to get world class innovations to patients. . Hamish Ryder.

HR 52

HR Research Drugs Development 52

Drug Discovery World

NOVEMBER 30, 2023

In addition, the company presented three posters: ‘Integration of next-generation transposon vectors with state-of-art host cell lines’, ‘Application of gene editing technologies to improve biotherapeutic manufacturing’, and ‘CHOSOURCE ADCC+ cell line for enhanced therapeutic potency’.

Antibody 59

Antibody Protein Engineer In-Vivo 59